文献速递脑血管病

ABCB1基因多态性与氯吡格雷治疗小卒中或TIA疗效的关联

Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2019-01-01

ABCB1多态性应被视为影响氯吡格雷疗效的因素。

要点

  • ABCB1 -154 TC/CC或3435 CT/TT基因型携带者占75.7%,联合治疗未显著获益。
  • 无上述基因型者联合治疗显著降低3个月卒中复发风险(HR 0.43)。
  • ABCB1与CYP2C19多态性对卒中复发存在联合关联。

核心结论

  • ABCB1多态性与小卒中或TIA患者氯吡格雷联合阿司匹林疗效降低相关,处方氯吡格雷时应考虑ABCB1基因型。

研究设计与样本

  • CHANCE随机临床试验的预设二次分析,纳入中国73个中心3010例小卒中或TIA患者,2836例进行基因分型。

主要发现

  • ABCB1 -154 TC/CC或3435 CT/TT基因型携带者中,氯吡格雷联合阿司匹林较阿司匹林未显著降低新发卒中风险(HR 0.78,95%CI 0.60-1.03)。
  • ABCB1与CYP2C19多态性对新发卒中风险存在联合关联。

关键数值与推荐

  • ABCB1 -154 TC/CC或3435 CT/TT基因型携带者占75.7%(2146/2836)。
  • 主要疗效结局为3个月卒中复发,安全结局为3个月任何出血。

临床怎么用

  • 对小卒中或TIA患者处方氯吡格雷前,可考虑检测ABCB1基因型以评估联合抗血小板治疗的预期获益。

局限性

  • 本研究为CHANCE试验的二次分析,结论需前瞻性验证。
  • 仅纳入中国人群,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Genetic variants of ABCB1 may affect intestinal absorption of clopidogrel bisulfate. However, it is unclear whether ABCB1 polymorphisms are associated with clopidogrel efficacy for minor ischemic stroke or transient ischemic attack (TIA). OBJECTIVES: To investigate the association between ABCB1 polymorphisms and clopidogrel efficacy for minor stroke or TIA. DESIGN, SETTING, AND PARTICIPANTS: In this prespecified secondary analysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events (CHANCE) randomized clinical trial, 3010 patients with minor stroke or TIA at 73 sites in China with experience in conducting genetic studies were included from October 1, 2009, to July 30, 2012. The analysis was conducted on March 20, 2018. Four single-nucleotide polymorphisms (ABCB1 -154T>C [rs4148727], ABCB1 3435C>T [rs1045642], CYP2C19*2 [681G>A, rs4244285], and CYP2C19*3 [636G>A, rs4986893]) were genotyped among 2836 patients treated with clopidogrel plus aspirin (n = 1414) or aspirin alone (n = 1422). The association of ABCB1 genetic variants (-154 TC/CC and 3435 CT/TT) with clopidogrel efficacy was evaluated in the context of CYP2C19 status, another gene associated with clopidogrel efficacy. INTERVENTIONS: Patients in the CHANCE trial were randomized to treatment with clopidogrel combined with aspirin or to aspirin alone. MAIN OUTCOMES AND MEASURES: Primary efficacy outcome was stroke recurrence after 3 months. The safety outcome was any bleeding risk after 3 months. RESULTS: Among 2836 patients, the median age was 61.8 years (interquartile range, 54.4-71.1 years) and 1887 patients (66.5%) were male. A total of 2146 (75.7%) patients were carriers of ABCB1 -154 TC/CC (570 [20.1%]) or 3435 CT/TT (1851 [65.3%]) genotype. Clopidogrel plus aspirin treatment was associated with reduced risk of new stroke in patients with ABCB1 -154 TT and 3435 CC genotype (hazard ratio [HR], 0.43; 95% CI, 0.26-0.71) but not in those with ABCB1 -154 TC/CC or 3435 CT/TT genotype (HR, 0.78; 95% CI, 0.60-1.03) compared with aspirin (P = .04 for interaction). A combined association of ABCB1 and CYP2C19 polymorphisms with new stroke was observed. The risk of bleeding for clopidogrel plus aspirin treatment was not associated with the ABCB1 genotypes (2.3% and 1.3% vs 1.9% and 2.2%; P = .25 for interaction in patients with or without ABCB1 -154 TC/CC or 3435 CT/TT genotype). CONCLUSIONS AND RELEVANCE: The ABCB1 polymorphism was associated with the reduced efficacy of clopidogrel plus aspirin treatment compared with aspirin among patients with minor ischemic stroke or TIA. Genetic polymorphism of ABCB1 should be considered when prescribing clopidogrel for these patients. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00979589.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Pan Y, Chen W, Wang Y, et al. Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial. JAMA Neurol. 2019. PMID: 30742211. doi:10.1001/jamaneurol.2018.4775

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。